公司公告汇总：振德医疗2024年年度股东大会于2025年5月19日召开，审议通过多项议案 公司公告汇总 截至2025年5月23日收盘，振德医疗（603301）报收于20.58元，较上周的20.18元上涨1.98%。本周，振 德医疗5月23日盘中最高价报20.79元。5月19日盘中最低价报20.08元。振德医疗当前最新总市值54.84亿 元，在医疗器械板块市值排名55/126，在两市A股市值排名2645/5148。 本周关注点 振德医疗2024年年度股东大会于2025年5月19日14点在浙江省绍兴市越城区皋埠街道香积路55号振德医 疗用品股份有限公司会议室召开，由董事长鲁建国主持。网络投票时间为2025年5月19日9:15-15:00。会 议审议并通过了以下议案：《公司2024年度董事会工作报告》《公司2024年度监事会工作报告》《关于 公司2024年度报告全文及其摘要的提案》《公司2024年度独立董事述职报告》《公司2024年度财务决算 报告》《关于公司2024年度利润分配方案》《关于公司开展远期外汇交易业务的提案》《关于公司2025 年度申请综合授信额度暨在授信额度内为子公司提供担保的提案》《关于续聘会计师 ...

Core Viewpoint - The medical protective clothing industry has experienced significant growth due to the COVID-19 pandemic, leading to increased production capacity and supply in China. However, as the pandemic situation stabilizes, demand has begun to decline, prompting a shift towards international markets. In 2024, production is expected to rebound, reaching 6.5 million sets, an increase of 8.3% year-on-year [1][11]. Industry Overview - Medical protective clothing serves as essential attire for healthcare personnel, providing safety and preventing the spread of pathogens. It includes various types of clothing based on usage, lifespan, and material processing methods [3][4]. - The industry is characterized by a high market concentration, dominated by several large enterprises that leverage technological innovation and brand development to capture significant market shares [15][16]. Industry Chain - The medical protective clothing industry chain consists of raw material supply, manufacturing, and distribution. Key raw materials include non-woven fabrics and functional materials, which are critical for product quality [9]. Current Industry Status - The demand for medical protective clothing surged during the pandemic, leading to rapid capacity expansion in China. As of 2023, demand has started to decline, with some production capacity redirected to international markets. In 2024, production is projected to increase to 6.5 million sets [1][11]. Competitive Landscape - Major companies in the medical protective clothing market include Blue Sail Medical, Shenzhen Shangrong Medical, and ZhenDe Medical. These companies are focusing on product differentiation and specialized markets to maintain competitiveness [15][16]. Development Trends - Quality Upgrade: There is a growing emphasis on product quality and functionality, with advancements in technology leading to the incorporation of features like antibacterial and antiviral materials [20]. - Personalization and Functionality: The industry is moving towards personalized products to meet the diverse needs of healthcare professionals [21]. - Smart and Technological Integration: The future of the industry includes the adoption of smart technologies for enhanced functionality and safety [22][23]. - Internationalization and Standardization: The industry aims to participate in international markets and promote product and industry standardization to enhance quality and reduce trade barriers [24].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhend Medical, which closed at 20.55 yuan with a PE ratio of 15.08, marking a 15-day low, and a total market capitalization of 5.476 billion yuan [1][2] - Zhend Medical ranks 34th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1][2] - As of the first quarter of 2025, 15 institutions hold shares in Zhend Medical, with a total holding of 154.3014 million shares valued at 3.331 billion yuan [1] Group 2 - The main business of Zhend Medical includes the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest financial results for the first quarter of 2025 show Zhend Medical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1]

证券代码：603301 证券简称：振德医疗 公告编号：2025-016 振德医疗用品股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 19 日 (二)股东大会召开的地点：浙江省绍兴市越城区皋埠街道香积路 55 号振德医 疗 用品股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 171 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 175,628,900 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 65.9140 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 本次会议由公司董事会召集，以现场投票和网络投票相结合的方式召开，由 董事长鲁建国先生主持会议。本次会议的召 ...

新业路 8号华联时代大厦 B 幢22层 电话: 0571-88362156 传真:0571-88362156 邮编:310016 北京国枫(杭州)律师事务所 关于振德医疗用品股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]G0009 号 致: 振德医疗用品股份有限公司(贵公司) 北京国枫(杭州)律师事务所(以下简称"本所")接受贵公司的委托,指派律师 出席并见证贵公司 2024年年度股东大会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《振德医疗用品股份 有限公司章程》(以下简称"《公司章程》"）的规定,就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本法律意见书。 对本法律意见书 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][23]. Core Insights - The company reported a revenue of 4.264 billion yuan in 2024, reflecting a growth of 3.32%, while the net profit attributable to shareholders increased significantly by 94.14% to 385 million yuan [2][4]. - In Q1 2025, the company achieved a revenue of 999.2 million yuan, a growth of 2.87%, but the net profit decreased by 30.19% to 51 million yuan [2][4]. - The company has expanded its distribution channels, covering nearly 9,000 hospitals across China and achieving a 99% coverage rate in the top 100 retail pharmacy chains [8]. Financial Performance Summary - **2024 Financials**: Total revenue was 4.264 billion yuan, with a net profit of 385 million yuan. The core business, excluding isolation protective products, saw a revenue increase of 15.80% [4][8]. - **2025 Projections**: Expected revenue growth of 12.6% to 4.8 billion yuan, with net profit projected to reach 439 million yuan, a 14% increase [4][9]. - **Earnings Per Share (EPS)**: Projected EPS for 2025 is 1.65 yuan, with a price-to-earnings (P/E) ratio of 12 [4][9]. Market Expansion - The company has made significant strides in both domestic and international markets, with domestic revenue from core business growing by 18.08% and overseas revenue increasing by 14.64% [8]. - The company has established an international marketing center and is penetrating markets in Southeast Asia, the Middle East, North America, and South America [8]. Investment Recommendations - The report adjusts the net profit forecast for 2025-2027 to 440 million, 510 million, and 590 million yuan respectively, with corresponding P/E ratios of 12, 10, and 9 [8][9]. - A discounted cash flow (DCF) model estimates the company's overall valuation at 7.5 billion yuan, leading to a target price of approximately 28 yuan per share [8].

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][4][23]. Core Insights - The company reported a revenue of 4.264 billion yuan in 2024, reflecting a growth of 3.32%, while the net profit attributable to shareholders increased significantly by 94.14% to 385 million yuan [2][4]. - In Q1 2025, the company achieved a revenue of 992 million yuan, a year-on-year increase of 2.87%, but the net profit decreased by 30.19% to 51 million yuan [2][4]. - The company has expanded its distribution channels, covering nearly 9,000 hospitals across China and achieving a 99% coverage rate in the top 100 chain pharmacies [8]. Financial Performance Summary - **2024 Financials**: Total revenue was 4.264 billion yuan, with a net profit of 385 million yuan. The core business revenue, excluding isolation protective products, grew by 15.80% [4][8]. - **2025 Projections**: Expected revenue growth of 12.6% to 4.8 billion yuan, with net profit projected to reach 439 million yuan, a 14% increase [4][9]. - **Earnings Per Share (EPS)**: Projected EPS for 2025 is 1.65 yuan, with a price-to-earnings (P/E) ratio of 12 [4][9]. Market Expansion - The company has seen robust growth in both domestic and international markets, with overseas revenue reaching 2.475 billion yuan in 2024, a 14.64% increase [8]. - The company has established an international marketing center and is making inroads into North and South American markets [8]. Investment Recommendations - The report adjusts the net profit forecast for 2025-2027 to 440 million, 510 million, and 590 million yuan respectively, with corresponding P/E ratios of 12, 10, and 9 [8][9]. - A discounted cash flow (DCF) model estimates the company's overall valuation at 7.5 billion yuan, leading to a target price of approximately 28 yuan per share [8].

截至2025年5月9日收盘，振德医疗(603301)报收于19.42元，下跌0.87%，换手率1.06%，成交量2.83万 手，成交额5501.15万元。 当日关注点 交易信息汇总 5月9日，振德医疗的资金流向情况如下：主力资金净流入469.81万元，占总成交额8.54%；游资资金净 流出1250.8万元，占总成交额22.74%；散户资金净流入780.98万元，占总成交额14.2%。 2024年，公司实现营业收入42.64亿元，同比增长3.32%，归属于母公司所有者的净利润3.85亿元，同比 增长94.14%。 公司公告汇总 振德医疗用品股份有限公司将于2025年5月19日下午14点00分在浙江省绍兴市越城区皋埠街道香积路55 号召开2024年年度股东大会。会议将审议以下议案：- 公司2024年度董事会工作报告- 监事会工作报告- 年度报告全文及其摘要- 财务决算报告- 利润分配方案：公司计划以266,321,760股为基数，每10股派发 现金红利6.50元（含税），合计派发现金红利173,109,144元（含税）- 开展远期外汇交易业务：年度总 金额不超过35,000万美元- 申请综合授信额度暨为子公司提供 ...

Core Viewpoint - Zhendemedical (603301) has shown a positive performance with a stock price increase of 1.46% this week, closing at 19.42 yuan, reflecting a stable growth trend in the medical device sector [1] Company Announcements - Zhendemedical will hold its 2024 Annual General Meeting on May 19, 2025, to review several proposals including the 2024 Board of Directors' report, Supervisory Board report, annual report, financial settlement report, profit distribution plan, and other business matters [1][3] - The company plans to conduct forward foreign exchange trading with a total annual amount not exceeding 35 million USD and will seek a comprehensive credit facility from financial institutions not exceeding 200 million RMB [2][3] - The company intends to reappoint Tianjian Accounting Firm for the 2025 financial audit and internal control audit [2][3] Performance Disclosure Highlights - In 2024, Zhendemedical achieved an operating income of 4.264 billion yuan, representing a year-on-year growth of 3.32%, while the net profit attributable to the parent company was 385 million yuan, showing a significant year-on-year increase of 94.14% [1][3] - The company plans to distribute a cash dividend of 6.50 yuan (including tax) for every 10 shares, totaling 173.11 million yuan (including tax) [1][3]

Meeting Agenda - The 2024 Annual General Meeting of Shareholders will cover various reports including the independent director's report, financial settlement report, profit distribution proposal, and proposals for foreign exchange trading and credit limits for subsidiaries [1][2][3] Company Performance - In 2023, the company achieved a revenue of 4.264 billion yuan, a 3.32% increase year-on-year, with a net profit attributable to shareholders of 385 million yuan, a 94.14% increase [4][5] - The revenue from isolation protective products was 160 million yuan, a decrease of 4.23 billion yuan year-on-year, while excluding these products, the revenue grew by 15.80% [4][5] Market Strategy - The company focuses on core areas such as surgical infection control and rehabilitation, enhancing market competitiveness through strategic planning and operational efficiency [6][7] - The company has expanded its coverage to nearly 9,000 hospitals across China, with over 1,200 being top-tier hospitals [6] Retail Market Development - The company has achieved a retail revenue of 594 million yuan, with a 9.77% increase year-on-year when excluding isolation protective products [8] - The company has established a strong presence in both online and offline retail channels, covering 99% of the top 100 pharmacy chains in China [7][8] International Expansion - The company is actively developing production bases in Africa and Mexico to enhance its international market competitiveness and meet diverse supply chain needs [9][10] - The overseas revenue reached 2.475 billion yuan, a 14.64% increase year-on-year, driven by strong performance in Southeast Asia and the Middle East [10] Research and Development - The company has focused on innovative product development in areas such as wound care and infection control, with significant investments in R&D [11][12] - The company has obtained 9 new medical device registrations and 28 patents, totaling 105 patents and 136 medical device registrations [12] Governance and Compliance - The board of directors has adhered to legal regulations and company bylaws, ensuring compliance and effective decision-making [19][20] - The company has implemented a profit distribution plan, distributing a total of 133.16 million yuan in cash dividends [21] Future Plans - The company aims to enhance its governance structure, expand market penetration, and strengthen R&D investments in 2025 [22][23] - The company will focus on product strategy, brand building, and digital transformation to improve operational efficiency and market presence [24][25]